Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

A multicentre, retrospect… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.

Artikel i vetenskaplig tidskrift
Författare Bertil Lindblom
Jean-Philippe Nordmann
Eric Sellem
Enping Chen
R Gold
Werner Polland
W Williamson
Patricia Buchholz
John G Walt
Danielle Groleau
Alistair Curry
Stacy J Evans
Publicerad i Acta ophthalmologica Scandinavica
Volym 84
Nummer/häfte 1
Sidor 74-83
ISSN 1395-3907
Publiceringsår 2006
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering
Sidor 74-83
Språk en
Länkar dx.doi.org/10.1111/j.1600-0420.2005...
Ämnesord Aged, Antihypertensive Agents, economics, Cost-Benefit Analysis, Drug Costs, Female, France, Glaucoma, Open-Angle, economics, therapy, Health Care Costs, Health Resources, economics, utilization, Humans, Intraocular Pressure, Male, Ocular Hypertension, economics, therapy, Ophthalmologic Surgical Procedures, economics, Retrospective Studies, Sweden
Ämneskategorier Oftalmiatrik

Sammanfattning

PURPOSE: To assess resource utilization and costs associated with glaucoma management in France and Sweden. METHODS: A total of 267 patient records (121 in France, 146 in Sweden) with diagnoses of primary open-angle glaucoma (POAG) and ocular hypertension (OH), treated medically, were reviewed for a 2-year period (beginning during 1997-99) for relevant clinical and resource utilization data. Economic data were applied to estimate treatment costs. RESULTS: The annual cost of treating glaucoma was estimated at SEK5305 (531 euro )/patient in Sweden and 390 euro/patient in France. In both countries, medication costs comprised about half of the total costs. Surgical procedures and hospitalizations represented greater proportions of total cost in France (7.0% and 9.6%, respectively) than in Sweden (3.7% and 0.6%, respectively). CONCLUSION: Medication costs represent a high proportion of total treatment costs. These findings highlight the relative importance of medical therapy and of assessing the cost-effectiveness of medications in glaucoma.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?